As of Nov 4, 2026. Rebuilt every trading night.
BIB daily tracking
Over the 90 days to Nov 4, 2026, BIB missed two times Nasdaq Biotechnology's daily return by 20.5 basis points a day on average, on its closing price.
All 5
5 of 5 · click a column to sort| # | Window | Read on | Average daily miss, bp | Signed average, bp | Tracking error | Up days, bp | Down days, bp | Up less down, bp | Confidence |
|---|---|---|---|---|---|---|---|---|---|
| 30 days to Nov 4, 2026: 13 of 22 days, from Oct 7, 2026 | NAV | 2.9 | −0.5 | 0.76% | −2.0 (7 days) | +1.1 (6 days) | −3.1 | Not enough days | |
| 30 days to Nov 4, 2026, 22 daily returns | closing price (stated) | 22.1 | −1.0 | 4.34% | −10.2 (13 days) | +12.2 (9 days) | −22.4 | Not enough days | |
| 90 days to Nov 4, 2026, 63 daily returns | closing price (stated) | 20.5 | −2.2 | 4.37% | −6.2 (34 days) | +2.5 (29 days) | −8.8 | Not significant (t −1.3) | |
| 180 days to Nov 4, 2026, 124 daily returns | closing price (stated) | 19.3 | −2.0 | 3.99% | −5.5 (73 days) | +3.0 (51 days) | −8.5 | Not significant (t −1.9) | |
| 1 year to Nov 4, 2026, 251 daily returns | closing price (stated) | 16.4 | −2.1 | 4.05% | −2.8 (137 days) | −1.2 (114 days) | −1.6 | Not significant (t −0.5) |
BIB's largest daily misses
The 5 days BIB strayed furthest from its daily target in the 1 year to Nov 4, 2026, each on its NAV where ETFIQ holds it, else its closing price.
| # | Day | Read on | Nasdaq Biotechnology moved | Target | BIB returned | Miss |
|---|---|---|---|---|---|---|
| 1 | Nov 13, 2025 | closing price | −0.15% | −0.31% | −2.10% | −1.79 pts |
| 2 | Nov 14, 2025 | closing price | −0.08% | −0.16% | +1.35% | +1.51 pts |
| 3 | Sep 24, 2026 | closing price | +0.60% | +1.21% | +1.99% | +0.78 pts |
| 4 | Jul 21, 2026 | closing price | +1.78% | +3.56% | +2.83% | −0.73 pts |
| 5 | Sep 23, 2026 | closing price | −1.81% | −3.62% | −4.30% | −0.69 pts |
The daily miss is BIB's return each day less two times Nasdaq Biotechnology's return that day. A basis point is a hundredth of a percentage point. Each window is read twice where ETFIQ holds both NAVs: on NAVs, and on closing prices. It is stated on the closing price because NAVs for 13 of the 63 sessions. BIB ranks 182 of 494 2x leveraged ETFs on its 90-day average daily miss.
The rest of the method
Up days and down days split the miss by whether Nasdaq Biotechnology rose or fell; Significant means the gap is at least two standard errors from zero. The average miss carries its sign: a negative one is what the fund kept below its target each day, its fees and financing among it. Nasdaq Biotechnology is itself an ETF, so its own fee and tracking are inside the miss. Not every fund here has traded for a year, and a number over eight months does not order against one over twelve. This page lists each fund with its window and dates instead of ranking them. It becomes a ranking on the night four of them share a full year. Every window ETFIQ can measure for BIB is listed.
Links are sources, not endorsements. A ranking is not a recommendation or an opinion.
Cite this pageCitation, APA and Markdown
ETFIQ, BIB daily tracking, listed by window, data as of Nov 4, 2026. https://etfiq.com/funds/bib/tracking/
ETFIQ. (Nov 4, 2026). BIB daily tracking, listed by window. Retrieved from https://etfiq.com/funds/bib/tracking/
[BIB daily tracking, listed by window (ETFIQ, Nov 4, 2026)](https://etfiq.com/funds/bib/tracking/)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms. The underlying files are at Open data.